Last updated: February 23, 2026
What is the drug associated with NDC 00078-0743?
NDC 00078-0743 corresponds to Humira (adalimumab) 40 mg prefilled pen, manufactured by AbbVie. It is a biologic used for autoimmune conditions, including rheumatoid arthritis, Crohn's disease, and psoriasis.
How does the current market landscape look?
Market size and demand
- The global adalimumab market was valued at approximately USD 24 billion in 2022.
- The U.S. accounts for over 50% of sales, driven by high prevalence of autoimmune diseases.
- Projected CAGR (2023–2028): 4–6%, driven by increasing diagnoses and biosimilar entry.
Competitive environment
- Humira maintains leading market share despite biosimilar competition.
- Key biosimilars launched from September 2023 onward include Amgen's Amjevita and Samsung Bioepis' Hadlima.
- Market share shifted from 86% in 2018 to approximately 60% post-biosimilar launch.
Regulatory Status
- Original Humira patents expired or are expiring in the U.S., with biosimilar approval occurring in 2023.
- Patent cliff has led to price reductions but retains value due to brand loyalty and manufacturing quality.
Pricing landscape
- List Price (United States): Approximately USD 6,000 per 40 mg pen.
- Actual Pharmacy and patient rebates lower net prices to approximately USD 1,200–USD 2,000 per pen.
- Biosimilar prices: 15–30% lower than Humira list prices initially; some discounts acquired in negotiations.
What are the pricing trends and projections?
Short-term (2023–2025)
- Biosimilars will continue to erode Humira’s market share, leading to a 20–30% reduction in net price over two years.
- Price competition among biosimilars may lower the average price of adalimumab therapies to USD 900–USD 1,500 per pen.
- Rebates and discounts will persist as key market dynamics, maintaining some price pressure.
Mid-term (2026–2030)
- Patent exclusivity further diminishes; biosimilar penetration stabilizes at 70–80% market share.
- List prices for original Humira are expected to decline 40–50% from peak levels.
- Biosimilar prices will undergo further reductions, approaching USD 700–USD 1,000 per pen.
- Market consolidation and payer negotiations will influence final net prices.
Long-term outlook
- Competition from next-generation biologics and increased biosimilar introduction could reduce prices further.
- Development of oral small-molecule alternatives might impact demand.
- Estimated average net price (2030): USD 800–USD 1,200 per pen.
What are the key factors influencing future pricing?
- Patent litigation and expiry: Major patents ending in the U.S. as of 2023.
- Biosimilar market entry: Increases competition leading to downward pricing.
- Payer negotiations: Managed care formulary strategies will impact net prices.
- Regulatory changes: Potential new policies on biosimilars and interchangeability.
- Manufacturing costs: Biological complex manufacturing keeps prices above generics costs.
Summary table of projections
| Year |
Estimated List Price (USD) |
Estimated Net Price (USD) |
Biosimilar Market Share |
| 2023 |
6,000 |
1,200–2,000 |
20% |
| 2025 |
4,200–5,400 |
900–1,500 |
40% |
| 2030 |
3,000–3,600 |
800–1,200 |
70–80% |
Key Takeaways
- Original Humira remains a high-value biologic, but pricing will decline significantly over the next decade.
- Biosimilar competition is the primary driver of price reduction, with discounts of 15–30% initially.
- Net prices are expected to stabilize around USD 800–USD 1,200 per pen by 2030.
- Market share will shift toward biosimilars, but branded Humira maintains influence due to loyalty and distribution channels.
- Future pricing depends on patent litigation, payer negotiations, and regulatory shifts.
FAQs
1. How will biosimilar entry impact Humira's market share?
Biosimilars are expected to capture 70–80% of the market by 2030, reducing Humira’s share from around 60–70% in 2023.
2. Will the list price of Humira decrease?
Yes, list prices are projected to fall 40–50% from peak levels by 2030 due to biosimilar competition and patent expirations.
3. Are there any major regulatory changes affecting pricing?
Potential policies promoting biosimilar substitution and stricter patent enforcement could influence prices and market dynamics.
4. What is the likely net price for the drug in the next five years?
Net prices are expected to decline to USD 900–USD 1,500 per pen within two years and stabilize around USD 800–USD 1,200 by 2030.
5. How will payer strategies influence future prices?
Managed care plans and formulary negotiations will exert downward pressure on net prices, especially as biosimilars become dominant.
Sources
- EvaluatePharma. (2023). Biologics market data and projections.
- IQVIA. (2023). U.S. pharmaceutical market analysis reports.
- FDA. (2023). Biosimilar approval and patent information.
- IQVIA. (2022). Biosimilar market entry and market share shifts.
- FDA. (2023). Patent and exclusivity data for Humira.
